University of Massachusetts Medical School

eScholarship@UMMS

Open Access Articles Open Access Publications by UMMS Authors

2020-01-15

Glycan profiles of gp120 protein vaccines from four major HIV-1 subtypes produced from different host cell lines under non-GMP or GMP conditions

Shixia Wang
University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Amino Acids, Peptides, and Proteins Commons, Immunology of Infectious Disease Commons, Immunoprophylaxis and Therapy Commons, Virology Commons, Virus Diseases Commons, and the Viruses Commons

Repository Citation

Wang S, Voronin Y, Zhao P, Ishihara M, Mehta N, Porterfield M, Chen Y, Bartley C, Hu G, Han D, Wells L, Tiemeyer M, Lu S. (2020). Glycan profiles of gp120 protein vaccines from four major HIV-1 subtypes produced from different host cell lines under non-GMP or GMP conditions. Open Access Articles. https://doi.org/10.1128/JVI.01968-19. Retrieved from https://escholarship.umassmed.edu/oapubs/4127

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

JVI Accepted Manuscript Posted Online 15 January 2020
J. Virol. doi:10.1128/JVI.01968-19
Copyright © 2020 Wang et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

1 **Glycan profiles of gp120 protein vaccines from four major HIV-1 subtypes**
2 **produced from different host cell lines under non-GMP or GMP conditions**
3

4 Shixia Wang[a,b], Yegor Voronin[b], Peng Zhao[c], Mayumi Ishihara[c], Nickita Mehta[c], Mindy
5 Porterfield[c], Yuxin Chen[a], Christopher Bartley[d], Guangnan Hu[a], Dong Han[a], Lance
6 Wells[c], Michael Tiemeyer[c], Shan Lu[a#]
7
8 [a]Department of Medicine, University of Massachusetts Medical School, Worcester, MA;
9 [b]Worcester HIV Vaccine, Inc., Worcester, MA;
10 [c]Complex Carbohydrate Research Center, University of Georgia, Athens, GA;
11 [d]Waisman Biomanufacturing, Madison, WI;
12
13
14

15 **Running Title:** HIV-1 gp120 protein glycan profiles
16 **Key Words:** HIV-1, gp120, Env protein, glycosylation, vaccine
17 **Abstract length:** 234 words
18 **Manuscript length:** 5277 words
19

20 **#Corresponding Author:**
21 Shan Lu
22 Department of Medicine
23 University of Massachusetts Medical School
24 55 Lake Avenue North, Worcester, MA 01532
25 Phone: 508-856-6791
26 Email: shan.lu@umassmed.edu

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online
Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

27

28 **Abstract**

29 Envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) is an
30 important target for the development of an HIV vaccine. Extensive glycosylation of Env
31 is an important feature that both protects the virus from antibody responses and serves
32 as a target for some highly potent broadly neutralizing antibodies. Therefore, analysis
33 of glycans on recombinant Env proteins is highly significant. Here we present
34 glycosylation profiles of recombinant gp120 proteins from four major clades of HIV-1 (A,
35 B, C, and AE) produced either as research-grade material in 293 and CHO cells or as
36 two independent lots of clinical material under GMP conditions. Almost all potential N-
37 linked glycosylation sites were at least partially occupied in all proteins. The occupancy
38 rates were largely consistent among proteins produced under different conditions,
39 although a few sites showed substantial variability even between two GMP lots. Our
40 data confirmed previous studies in the field showing high abundance of oligomannose
41 on Env protein, with 40-50% of glycans having Man_5-Man_9 on all four proteins under all
42 production conditions. Overall the differences in occupancy and glycan forms among
43 Env from different subtypes produced under different conditions were less dramatic than
44 anticipated and antigenicity analysis with a panel of six monoclonal antibodies showed
45 that all four gp120s maintained their antibody-binding profiles, including antibodies that
46 recognize glycan forms. Such findings have major implications to the final production of
47 a clinical HIV vaccine including Env glycoprotein components.

48

49

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

50 **Importance**

51 HIV-1 Env protein is a major target for the development of an HIV-1 vaccine. Env is
52 covered with a large number of sugar-based glycan forms – about 50% of the Env
53 molecular weight is composed of glycans. Glycan analysis of recombinant Env proteins
54 is important to understand its roles in vial pathogenesis and immune responses. The
55 current report presents the first extensive comparison of glycosylation patterns of
56 recombinant gp120 proteins from four major clades of HIV-1 produced in two different
57 cell lines, grown at either laboratory condition or at 50L GMP scale across different lots.
58 Information learned in this study is valuable for the further design and production of HIV-
59 1 Env proteins as the critical components of HIV-1 vaccine formulations.

60

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

61 **Introduction**

62 The envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) plays
63 the key role in viral entry and serves as a major target for a preventive HIV-1 vaccine.
64 Env is heavily glycosylated with N-glycans comprising about half of its molecular weight.
65 In the course of HIV-1 evolution, either within an individual patient or on the population
66 level, viral gene mutations may lead to the disappearance of certain glycosylation sites
67 and to the appearance of new ones. This shifting glycan shield protects the Env
68 proteins from the engagement of antibodies elicited during the course of viral infection
69 and contributing to the growth of escaping viral mutants in chronic infection (1).
70 Nevertheless, some glycan features are highly conserved even across clades such that
71 glycans contribute to several key antigenic domains recognized by broadly neutralizing
72 antibodies. For example, the highly conserved N332 glycan is important for the binding
73 of monoclonal antibodies (mAbs) PGT128 and 10-1074, while N160 glycan is
74 recognized by mAbs PG9 and PG16 (2, 3). Another conserved feature of HIV glycan
75 shield is high abundance of unusual oligomannose forms, which normally serve as
76 intermediates in mammalian glycan synthesis (4–6).
77
78 Glycosylation pattern can be expected to vary depending on multiple factors impacting
79 glycoprotein synthesis, including the viral strain, the form in which Env is expressed
80 (gp120, gp140, gp160), the cell type, the protein expression levels, and even the
81 metabolic state of the cell (7). In past studies, the exact proportion of oligomannose on
82 Env varied from 17% to 98% with levels of 40-75% being common for both monomeric
83 gp120 and native trimers (5, 8, 9). However, analysis of two batches of membrane-

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

84 anchored Env showed remarkable consistency of forms found at each glycosylation site
85 (9, 10), indicating that glycosylation patterns are generally preserved when the same
86 Env protein is produced under identical conditions and that the differences in
87 oligomannose content reflect either virus- or host cell specific factors.
88
89 In previous studies the viral clade-specific differences in the abundance of
90 oligomannose have been attributed to the differences in the total number and regional
91 density of the glycosylation sites, with higher glycan densities correlating with higher
92 oligomannose content (4). On the other hand, comparisons of glycosylation of the
93 same Env proteins expressed in 293 and CHO cells revealed mostly similar
94 oligomannose content, similar occupancy, and similar glycan profiles, but with some
95 notable exceptions (11, 12). It was observed that more complex glycans were present
96 on CHO-derived clade C gp120 as compared to 293-derived protein, particularly at two
97 sites (N386 and N392).
98
99 The increasing understanding of the impact of glycans on HIV Env immunogenicity and
100 the increased focus on recombinant Env proteins after the RV144 trial led to the
101 growing appreciation of the importance of these features to the design of Env-based
102 protein vaccines against HIV-1(13). In particular, characterization of glycan profiles of
103 recombinant Env proteins will be important to interpret the resulting antibody responses.
104
105 Various approaches of producing and purifying recombinant Envs for laboratory
106 research and for clinical studies can be employed, but there's limited information based

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

107 on well-controlled studies for how different approaches may impact Env glycosylation.
108 While transiently-transfected 293 cells are often used to produce research-grade
109 proteins, the proteins for clinical use are usually produced in stably transfected CHO
110 cells. Clinical material is usually produced in bioreactors that have larger volumes and
111 reach higher cell density than those used in research-grade protein production. Diverse
112 purification processes are used both in the lab and during clinical-grade protein
113 purification, such as antibody-based affinity columns, size-exclusion chromatography,
114 lectin-based columns, or the industry preferred ion-exchange columns. Recently, a few
115 recombinant GMP-grade Env-based vaccines have been characterized by analysis of
116 glycans (14, 15) but the number of Env proteins included in those studies was limited
117 and they did not provide direct comparison between different cell lines or between GMP
118 and non-GMP for the production of the same Env proteins.
119
120 Here we expanded the study to characterize glycosylation profiles of four recombinant
121 gp120 proteins from four major clades of HIV-1 (subtypes A, B, C, and AE) produced
122 under GMP condition for a Phase I human clinical trial (HVTN124). We analyze two
123 separate GMP lots of the same four gp120 proteins comparing them to the same four
124 gp120 proteins produced under non-GMP condition in CHO and 293F cells. Our results
125 provide much needed information on the Env glycan patterns among different viral
126 clades and between different preparations of the same protein. Such information is not
127 only valuable for the better understanding on the variation of Env glycan patterns but
128 also critical for the establishment of quality control standards for the production of
129 clinical grade Env-based HIV-1 vaccines.

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

130 **Results**

131 **HIV-1 gp120 Env proteins from four clades and produced under different**
132 **conditions**

133 The four gp120 glycoproteins included in the current study were selected based on the
134 immunogenicity analysis of a large panel of HIV-1 Env variants (16) and were included
135 in a polyvalent DNA prime-protein boost HIV vaccine formulation currently going
136 through a phase I clinical study at HIV Vaccine Trials Network (HVTN, protocol 124).
137 They represent three primary isolates from clades A, B, and C, as well as a consensus
138 variant from the AE clade. Their amino acid sequences have a low homology to each
139 other in the range of 75-80 % (Fig.1A). They have 23-26 potential N-linked
140 glycosylation sites (PNGSs), which are distributed throughout the sequence in a similar,
141 but distinct manner (Fig.1B).

142

143 Research-grade gp120 proteins were produced by transient transfection of 293F cells
144 and from stably-transfected CHO cells in a laboratory setting and the proteins were
145 purified using lectin-based columns. For the GMP manufacturing process, stably
146 transfected CHO cells expressing each of the proteins were grown in 50L bioreactors
147 and the purification process involved ion-exchange columns. Two separate GMP
148 manufacturing runs have been done under identical conditions, which allowed us the
149 opportunity to compare the consistency of glycosylation profiles from one GMP lot to
150 another.

151

152 **Glycan analysis of research-grade proteins**

Accepted Manuscript Posted Online
Journal of Virology
JVI
Journal of Virology

153 Glycan heterogeneity for gp120 proteins produced as research-grade reagents in CHO
154 and 293F cell lines were first analyzed. Digestion with PNGase F was used to release
155 glycans from the gp120 proteins and the released glycans were permethylated and
156 analyzed by NSI-MSn to characterize glycan structural features. Representative
157 profiles for clade B gp120 are shown on Fig. 2A. The types of glycan forms found on
158 proteins produced in CHO and 293F cells were generally very similar and only a few
159 types comprised more than 10% of the total glycans (Fig. 2B). A large proportion of
160 oligomannose forms (Man_7-Man_9) was detected in both preparations. A diverse group
161 of complex glycans were also present, as well as some hybrid forms. The results for
162 proteins from three other clades were similar (data not shown).
163
164 To study occupancy rate at each PNGS, proteins were digested with several proteases
165 to produce peptides for LC/MS analysis and then consecutively digested with EndoH
166 and PNGase F to allow detection of occupancy by different types of glycans at each
167 PNGS. Digestion with EndoH cleaves N-linked glycans between the two N-
168 acetylglucosamine (GlcNAc) residues in the core region of the glycan chain on high-
169 mannose and hybrid, but not complex, glycans, leaving one GlcNAc still bound to the
170 protein. Treatment with PNGase F removes all glycans that have not been impacted by
171 EndoH treatment and leaves an aspartic acid residue at the site of N-linked
172 glycosylation, which can be distinguished from the original asparagine by mass
173 spectrometry of the peptides. Therefore, consecutive digestion with EndoH and
174 PNGaseF allowed us to distinguish between oligomannose and complex glycans at

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

175 each site. The presence of the original asparagine in the peptide indicates that the
176 PNG site has not been glycosylated.
177
178 Analysis of PNGS occupancy of research grade 293F- and CHO-produced proteins
179 showed that most of PNGSs were at least partially occupied in both cases (Fig. 3A).
180 N141, N186 and N339 in clade B protein, N186 and N397 in clade C protein, and N465
181 in clade AE protein were the only sites that showed less than 20% occupancy in our
182 analysis. A large proportion of oliogomannose glycans was observed for all four gp120
183 proteins, with higher proportions in glycans described as innate mannose patch.
184
185 Glycosylation profiles of proteins produced in 293F and CHO cells were remarkably
186 similar (Fig. 3B). Most of the variation in occupancy was under 30 percentage points.
187 Clade B proteins showed the largest variation with CHO-produced protein being more
188 glycosylated than 293-produced protein. In some cases the changes were not in the
189 total occupancy, but in the relative abundance of oligomannose and complex glycans.
190 For example, N262 in clade B proteins was almost 100% occupied, but 293-produced
191 protein carried an equal mixture of oligomannose and complex glycans, and CHO-
192 produced proteins had almost exclusively oligomannose glycans at this site.
193
194 **Glycan profile analysis of four GMP-grade gp120 proteins**
195 The four GMP-grade gp120 proteins have been produced in stably expressing CHO cell
196 lines at 50L scale and purified using a multi-step chromatography. Two separate lots
197 have been manufactured using the same master cell bank CHO cells and the same

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Journal of Virology

Accepted Manuscript Posted Online

198 fermentation and downstream purification process, which allowed us to investigate the
199 lot-to-lot variability of GMP grade gp120 protein preparations. The glycan forms
200 identified from GMP grade gp120 proteins are shown in Fig.4, and the relative amounts
201 of these glycan forms between two GMP lots are show in Fig.5. For most gp120
202 proteins, oligomannose (Man_5-Man_9) constituted 40-50% of the total glycans, while
203 complex glycans were about 35-45%, and the rest were hybrid glycans or
204 paucimannose (Man_3-Man_4). The least-processed Man_9 and Man_8 forms predominated
205 on clade A and clade B gp120 proteins, while clade C and clade AE proteins showed
206 higher percentages of Man_5. Percentage of paucimannose showed the largest variation
207 both between the clades and especially between the two lots of clade C gp120 protein,
208 where in one of the lots paucimannose represented 23% of all glycans. Other proteins
209 showed a more consistent glycan composition for two independent lots. Complex
210 glycans were predominantly (63-87%) sialylated and >85% were core fucosylated
211 (Fig.6).
212
213 Thus all variants of GMP-grade gp120 proteins exhibited high proportion of
214 oligomannose glycans. The comparison of the two GMP lots showed mostly
215 comparable glycan composition for three tested variants of gp120 proteins (clades A, B
216 and AE) and some variation in the amount of paucimannose for clade C variant.
217
218 **PNGSs occupancy analysis of GMP-grade gp120 proteins**
219 Next, PNGS occupancy was mapped for proteins from one of the GMP lots and
220 compared to the CHO-produced research-grade proteins. The overall occupancy profile

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

221 of the GMP-grade gp120 proteins was generally similar to that of research-grade
222 proteins, although the GMP proteins tended to have higher proportion of complex
223 glycans (Fig.7). Analysis of the protein from the second lot did not reveal any major
224 differences with the first lot (data not shown).

225

226 The oligomannose glycans were not equally distributed among the PNGSs. N262,
227 N289/N295, N332, and N363 were enriched in oligomannose, corresponding to the
228 intrinsic mannose patch that has been noted for HIV Env previously. While present on
229 all four proteins, the patch was more pronounced for clade A, B, and C proteins, while
230 oligomannose was more evenly distributed on clade AE protein. Clade C had an
231 unusual enrichment in oligomannose at the C-terminus (N406, N442, N448, N463) that
232 was absent in the other three proteins.

233

234 **Antigenicity analysis among 4 gp120 proteins**

235 Finally, we sought to test whether any observed lot-to-lot variation in PNGS occupancy
236 and glycan composition, no matter how minor they may be, had an effect on key
237 antigenic features of these proteins. Using the affinity-measuring Octet Qke system and
238 a panel of probing reagents we tested the preservation of key epitopes on these four
239 gp120 protein: CD4 binding site (IgG-CD4 and mAb VRC01), V2 loop (mAb 2158), V3
240 region (mAb R16), gp120 bridging sheet and loop F overlapping with CD4bs (mAb
241 R53), and glycan forms (mAb 2G12 and mAb PGT128). The epitope for the 2G12
242 antibody is believed to include mannose-rich glycans at positions 295, 332, 392, 386,
243 and 448 (17). The PGT128 epitopes includes glycans at positions 332 and 301, as well
244 as the C-terminal end of the V3 loop (18). While we observed differences in affinities of

Journal of Virology JVI Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

245 these reagents, the differences between two lots of each clade were minimal (Table 1).
246 This includes similar affinity of glycan-dependent 2G12 and PGT128 to the lot 2 of clade
247 C protein, which exhibited the unusually high proportion of paucimannose compared to
248 lot 1. Thus, our results demonstrate that observed differences in glycan profiles did not
249 result in changes in affinity of antibodies targeting key epitopes of four gp120 proteins,
250 including glycan-binding antibodies, indicating that proteins produced under different
251 conditions mostly preserved their antigenic structure.
252

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

253 **Discussion**

254 This report presents the first extensive comparison of glycosylation patterns of
255 recombinant gp120 proteins from four clades of HIV-1 across two different cell lines,
256 grown either at laboratory scale or at 50L GMP conditions, purified using different
257 methods, and across two GMP lots under identical conditions. Our results show that in
258 all four gp120 proteins included in the current study, the majority of PNG sites were
259 occupied by glycans with occupancy rates usually above 50%. We also found that
260 among glycans found on these proteins, oligomannose forms represented 40-50% and
261 were concentrated in the previously described intrinsic mannose patch. At the same
262 time, glycosylation profiles were basically very similar, with a low level of variability
263 under different conditions. These differences did not affect binding by a panel of
264 antibodies targeting key immunologic epitopes of gp120 proteins, indicating that the
265 observed low level glycan differences should not have a major impact on protein
266 immunogenicity.

267

268 The most prominent feature of HIV Env glycans distinguishing them from glycans on
269 host proteins is the presence of oligomannose. In agreement with previous reports, we
270 observed high proportion of oligomannose glycans (Man_5-Man_9) on all four proteins
271 produced under all conditions confirming that this is a characteristic feature of HIV
272 envelope. Even though previous studies reported a rather wide range of the percentage
273 of oligommannose, we consistently observed that in all cases it constituted 40-50% of
274 glycans. At least one recent study reported that gp120 derived from infectious virions
275 contained 50% oligomannose glycans (19), which suggests that glycosylation patterns

Accepted Manuscript Posted Online

276 of native Env are generally preserved on the recombinant gp120 proteins. This
277 preservation is important for HIV vaccine development aiming to elicit antibodies that
278 bind and neutralize HIV virions.
279
280 The research-grade gp120 protein was produced in 293F and CHO cells and purified
281 using lectin columns, while the GMP-grade protein was produced in CHO cells grown at
282 50L scale and purified using ion exchange columns. Nevertheless, we found only minor
283 differences in glycan occupancy and glycan content between proteins produced under
284 different conditions, indicating that these features are primarily determined by viral
285 sequence and not by the producing cells or purification process.
286
287 Our comparison of two independent GMP-grade lots of gp120 proteins showed a
288 consistent glycosylation pattern between them, but also did show some differences,
289 including a significant increase in paucimannose content in one of the lots of clade C
290 protein. It should be noted that this particular lot differed from all other GMP lots in
291 having a significantly higher yield of the protein. We do not have enough data to
292 establish the causal relationship between these two observations, but hypothesize that
293 high levels of protein production overwhelmed medial and trans-Golgi glycan-
294 processing machinery in producing cells, resulting in secretion of proteins with glycans
295 that were fully trimmed by cis-Golgi mannosidases but incompletely branched,
296 extended, and capped. Further work is needed to test the factors impacting variability
297 of glycosylation during GMP manufacturing and acceptable variability levels should be

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

298 established. Special attention should be paid to optimizations that boost protein

299 production in cells as that may have an impact on cellular glycosylation machinery.

300

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

301 **Materials and Methods**

302 **Production of Non-GMP gp120 proteins**

303 The four gp120 glycoproteins used in this report are from HIV-1 clade A isolate
304 92UG037.8, clade B isolate JRFL, clade C isolate 93MW965.26 and clade AE
305 consensus, respectively (16). The non-GMP research grade HIV-1 gp120 proteins were
306 produced using two protein expression systems: transiently transfected 293F cell
307 expression and stably transfected CHO cell expression system. The codon optimized
308 gp120-coding DNA inserts cloned in the vector pJW4303 were used in both 293F and
309 CHO cells. To produce gp120 proteins from transiently transfect 293F cells, the serum-
310 free 293F cell supernatant was collected at 72 hours after transfection. To express
311 gp120 proteins from CHO cells, the serum-free culture supernatant of stable transfected
312 CHO cells were collected. The harvested gp120 proteins from both 293F and CHO
313 cells in research grade were purified using a Lectin column and verified by SDS-PAGE
314 and Western blot analysis as previously described (20–22).

315

316 **Production of GMP grade gp120 proteins**

317 The codon optimized gp120 gene inserts from the same four clades (A, B, C and AE) as
318 described above for research grade proteins were transfected into CHO DG44 cells
319 (Invitrogen, CA), respectively, and used to establish the master cell banks. Each of
320 these four gp120 expressing stable CHO GD44 cells were grown in 50L bioreactors and
321 the cell culture supernatants were collected after 8-10 days of fermentation and purified
322 through a down stream purification process including the anion-exchange, cation-
323 exchange and size-exclusion steps under the GMP conditions. The purity of each

Accepted Manuscript Posted Online

Journal of Virology

JVI

324 gp120 proteins is at the range of 96-98% based on their release certificates. The same
325 purified gp120 proteins are currently being tested in a Phase I clinical trial under
326 HVTN124 protocol at six major US medical centers.
327
328 **Detection of occupancy of N-linked glycosylation sites on gp120 proteins**
329 An aliquot of each gp120 protein was buffered to alkaline pH, reduced, alkylated, and
330 digested with a combination of proteases including Lys-C (Promega), Arg-C (Promega),
331 Glu-C (Promega), and trypsin (Promega). Following digestion, the proteins were
332 deglycosylated by Endo-H (Promega) followed by PNGaseF (Glyko®, Prozyme)
333 treatment in the presence of ^{18}O-water. The resulting peptides were separated on an
334 Acclaim PepMap RSLC C18 column (75 µm x 15 cm) and eluted into the nano-
335 electrospray ion source of an Orbitrap Fusion™ Lumos™ Tribrid™ mass spectrometer
336 (Thermo Fisher Scientific) with a 240-min linear gradient consisting of 0.8-80%
337 acetonitrile over 180 min at a flow rate of 200 nL/min. Full MS analysis was conducted
338 in the Orbitrap and automated MS/MS analysis using collision-induced dissociation was
339 conducted in the ion trap. Resulting data was analyzed using a combination of
340 Proteome Discover/Sequest and ProteoIQ/Provalt to generate a 1% false discovery rate
341 for protein assignments. Site occupancy was calculated using spectral counts assigned
342 to the ^{18}O-Asp-containing (PNGaseF-cleaved) and/or HexNAc-modified (EndoH-
343 cleaved) peptides and their unmodified counterparts. The positivity cut-off for spectral
344 counts was set at 10% of the spectral count for the most abundant peptide in each
345 LC/MS run. Peptides with spectral counts below the positivity cut-off were not included
346 in the analysis.

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

347

348 **N-linked glycan profiling analysis for gp120 proteins**

349 A 20 μg aliquot of each gp120 sample was denatured by boiling in SDS. Upon cooling,
350 the SDS was removed by precipitation as its potassium salt. Denatured proteins were
351 buffered, recombinant peptide-N-glycanase F (PNGaseF) was added, and the mixture
352 was incubated overnight to release N-linked glycans. The released N-linked glycans
353 were freed from residual enzyme, deglycosylated protein, and other contaminants by
354 passage over C18 Sep-pak. The released, purified glycans were permethylated using
355 methyliodide (CH_3I) under basic conditions in an aprotic solvent (DMSO), followed by
356 recovery through organic extraction. For mass spectrometric analysis, one-half of the
357 total permethylated glycans released from 20 μg of protein (10 μg equivalent of protein)
358 was supplemented by the addition of 10 pmol of an exogenous glycan standard
359 (maltotetraose) that had previously been permethylated with isotopically heavy
360 methyliodide ($^{13}CH_3I$). The sample glycans spiked with standard were directly infused
361 into an LTQ/Orbitrap mass spectrometer fitted with a nanospray ionization interface
362 (NSI-MSn; Orbitrap Discovery, Thermo-Fisher). Glycans were detected in full MS mode
363 and by total ion mapping (TIM), in which automated CID is performed on small,
364 overlapping m/z windows. TIM allows the unbiased detection of ions that give
365 fragmentation patterns consistent with glycan structural topologies (23). Glycan signal
366 intensities were recovered from extracted full MS spectra (Xtract, Thermo-Fisher) and
367 glycan identities were assigned based on exact mass and CID fragmentation.
368 Graphical representations of monosaccharide residues are presented in accordance
369 with the broadly accepted Symbolic Nomenclature For Glycans, SNFG, and glycan

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

370 analysis was performed in keeping with the MIRAGE guidelines for glycomic studies
371 (24, 25).
372

373 **IgG-CD4 protein and gp120-specific monoclonal antibodies (mAbs)**

374 The IgG-CD4 protein used in the Octet Qke assays was a fusion protein of human CD4
375 domains 1 and 2 with human IgG1 Fc at the C-terminus produced by transient
376 transfection of 293F cells and His-tagged purification. The gp120 CD4 binding site
377 (CD4bs) monoclonal antibody VRC01 (26) was produced from transiently transfected
378 293F cells using the molecular clones coding for VRC01 heavy and light chains
379 obtained from NIH AIDS Reagent Program and purified with a Protein A column. The
380 gp120 glycan-specific human mAb 2G12 (27) was purchased from Polymun. The
381 gp120 glycan specific mAb PGT128 (18) was provided by Wayne Koff from International
382 AIDS Vaccine Initiative (IAVI). The gp120-V2 specific human mAb 2158 (28) was
383 purchased from Dr. Susan Zolla-Pazner's lab at Mount Sinai School of Medicine. The
384 gp120 V3 and C4 specific rabbit mAbs R16 and R53 as reported (29, 30) were
385 produced from transiently transfected 293F cells using paired heavy and light chain
386 molecular clones and purified using a Protein A column. The IgG-CD4 protein and
387 monoclonal antibodies produced by this study were verified before use.
388

389 **Antigenicity analysis of gp120 proteins with Octet Qke**

390 The antigenicity of gp120 proteins was tested using IgG-CD4 and gp120-specific
391 monoclonal antibodies by Octet Qke (ForteBio) based on biolayer interferometry. The
392 IgG-CD4 or each gp120-specific human mAb was individually loaded on to Protein G
393 sensors at 20 μg/mL and the individual gp120-specific rabbit mAb was loaded to Protein

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

394 A sensors at 10 μg/mL diluted in ForteBio kinetics buffer. After capture, tips were
395 washed in kinetics buffer and a baseline measurement recorded. The tips were then
396 incubated in wells containing serial dilutions of individual gp120 protein (600nM-0.4nM)
397 to measure the association rate (Kon) and dissociation rate (Koff). The antibody binding
398 kinetics and KD values (Koff/Kon) were collected by the ForteBio Data Analysis
399 software package v7.1 using a 1:1 fitting model for IgG-CD4 and mAbs VRC01,
400 PGT128, 2G12, 2158 and R16, and using a 2:1 fitting model for mAb R53.
401
402
403

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

404 **Acknowledgements**

405 This study was supported in part by NIH grants U19AI082676, P01AI082274,

406 R01AI065250, R21/R33AI087191, U19AI09646, and R01AI39290, as well as by the

407 grant OPP1033112 from the Bill and Melinda Gates Foundation. The funders had no

408 role in study design, data collection and interpretation, or the decision to submit the

409 work for publication.

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

410 **References**

411

412 1. Reitter JN, Means RE, Desrosiers RC. 1998. A role for carbohydrates in immune
413 evasion in AIDS. Nat Med 4:679–684.

414 2. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A,
415 Gnanapragasam PNP, Spencer DIR, Seaman MS, Schuitemaker H, Feizi T,
416 Nussenzweig MC, Bjorkman PJ. 2012. Complex-type N-glycan recognition by
417 potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109:E3268–
418 E3277.

419 3. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T,
420 Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM,
421 Hammond PW, Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M,
422 Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies
423 from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289.

424 4. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M,
425 Scanlan CN. 2011. The glycan shield of HIV is predominantly oligomannose
426 independently of production system or viral clade. PloS One 6:e23521.

427 5. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M,
428 Scanlan CN. 2010. Envelope glycans of immunodeficiency virions are almost
429 entirely oligomannose antigens. Proc Natl Acad Sci U S A 107:13800–13805.

Accepted Manuscript Posted Online

430 6. Pritchard LK, Spencer DIR, Royle L, Bonomelli C, Seabright GE, Behrens A-J, Kulp
431 DW, Menis S, Krumm SA, Dunlop DC, Crispin DJ, Bowden TA, Scanlan CN, Ward
432 AB, Schief WR, Doores KJ, Crispin M. 2015. Glycan clustering stabilizes the
433 mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing
434 antibodies. Nat Commun 6:7479.

435 7. Stanley P, Taniguchi N, Aebi M. 2015. N-Glycans, p. . *In* Varki, A, Cummings, RD,
436 Esko, JD, Stanley, P, Hart, GW, Aebi, M, Darvill, AG, Kinoshita, T, Packer, NH,
437 Prestegard, JH, Schnaar, RL, Seeberger, PH (eds.), Essentials of Glycobiology,
438 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY).

439 8. Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao H-X, Sutherland LL, Alam SM,
440 Haynes BF, Desaire H. 2008. Glycosylation site-specific analysis of HIV envelope
441 proteins (JR-FL and CON-S) reveals major differences in glycosylation site
442 occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome
443 Res 7:1660–1674.

444 9. Go EP, Chang Q, Liao H-X, Sutherland LL, Alam SM, Haynes BF, Desaire H.
445 2009. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J
446 Proteome Res 8:4231–4242.

447 10. Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, Mao Y, Chen H, Ding
448 H, Wakefield JK, Hua D, Liao H-X, Kappes JC, Sodroski J, Desaire H. 2015.
449 Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1
450 Envelope Glycoprotein Trimers and Soluble gp140. J Virol 89:8245–8257.

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Journal of Virology JVI Journal of Virology

Accepted Manuscript Posted Online

451 11. Go EP, Liao H-X, Alam SM, Hua D, Haynes BF, Desaire H. 2013. Characterization
452 of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1
453 gp120 envelope proteins. J Proteome Res 12:1223–1234.

454 12. Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, Ringe R, Kim HJ,
455 Sanders RW, Doores KJ, Burton DR, Wilson IA, Ward AB, Moore JP, Crispin M.
456 2015. Structural Constraints Determine the Glycosylation of HIV-1 Envelope
457 Trimers. Cell Rep 11:1604–1613.

458 13. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R,
459 Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S,
460 Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S,
461 Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH.
462 2009. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in
463 Thailand. N Engl J Med 361:2209–20.

464 14. Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P,
465 Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P,
466 Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy
467 R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB,
468 Zolla-Pazner S, Liao H-X, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ,
469 Carfi A, Barnett SW. 2018. Generation and characterization of a bivalent protein
470 boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with
471 a potent adjuvant. PloS One 13:e0194266.

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

472 15. Zambonelli C, Dey AK, Hilt S, Stephenson S, Go EP, Clark DF, Wininger M,
473 Labranche C, Montefiori D, Liao H-X, Swanstrom RI, Desaire H, Haynes BF, Carfi
474 A, Barnett SW. 2016. Generation and Characterization of a Bivalent HIV-1 Subtype
475 C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in
476 Southern Africa. PloS One 11:e0157391.

477 16. Wang S, Chou T-H, Hackett A, Efros V, Wang Y, Han D, Wallace A, Chen Y, Hu G,
478 Liu S, Clapham P, Arthos J, Montefiori D, Lu S. 2017. Screening of primary gp120
479 immunogens to formulate the next generation polyvalent DNA prime-protein boost
480 HIV-1 vaccines. Hum Vaccines Immunother 13:2996–3009.

481 17. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO,
482 Kwong PD, Moore JP. 2002. The Mannose-Dependent Epitope for Neutralizing
483 Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. J
484 Virol 76:7293–7305.

485 18. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL,
486 Julien J-P, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A,
487 Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi
488 T, Scanlan CN, Wong C-H, Moore JP, Olson WC, Ward AB, Poignard P, Schief
489 WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody
490 recognizes and penetrates the HIV glycan shield. Science 334:1097–1103.

491 19. Struwe WB, Chertova E, Allen JD, Seabright GE, Watanabe Y, Harvey DJ, Medina-
492 Ramirez M, Roser JD, Smith R, Westcott D, Keele BF, Bess JW, Sanders RW,
493 Lifson JD, Moore JP, Crispin M. 2018. Site-Specific Glycosylation of Virion-Derived

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

494 HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell Rep 24:1958-
495 1966.e5.

496 20. Vaine M, Wang S, Hackett A, Arthos J, Lu S. 2010. Antibody responses elicited
497 through homologous or heterologous prime-boost DNA and protein vaccinations
498 differ in functional activity and avidity. Vaccine 28:2999–3007.

499 21. Wang S, Pal R, Mascola JR, Chou T-HW, Mboudjeka I, Shen S, Liu Q, Whitney S,
500 Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. 2006. Polyvalent HIV-1
501 Env vaccine formulations delivered by the DNA priming plus protein boosting
502 approach are effective in generating neutralizing antibodies against primary human
503 immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology
504 350:34–47.

505 22. Wang S, Kishko M, Wan S, Wang Y, Brewster F, Gray GE, Violari A, Sullivan JL,
506 Somasundaran M, Luzuriaga K, Lu S. 2012. Pilot study on the immunogenicity of
507 paired Env immunogens from mother-to-child transmitted HIV-1 isolates. Hum
508 Vaccines Immunother 8:1638–1647.

509 23. Aoki K, Perlman M, Lim J-M, Cantu R, Wells L, Tiemeyer M. 2007. Dynamic
510 developmental elaboration of N-linked glycan complexity in the Drosophila
511 melanogaster embryo. J Biol Chem 282:9127–9142.

512 24. Varki A, Cummings RD, Aebi M, Packer NH, Seeberger PH, Esko JD, Stanley P,
513 Hart G, Darvill A, Kinoshita T, Prestegard JJ, Schnaar RL, Freeze HH, Marth JD,
514 Bertozzi CR, Etzler ME, Frank M, Vliegenthart JF, Lütteke T, Perez S, Bolton E,

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

515 Rudd P, Paulson J, Kanehisa M, Toukach P, Aoki-Kinoshita KF, Dell A, Narimatsu
516 H, York W, Taniguchi N, Kornfeld S. 2015. Symbol Nomenclature for Graphical
517 Representations of Glycans. Glycobiology 25:1323–1324.

518 25. York WS, Agravat S, Aoki-Kinoshita KF, McBride R, Campbell MP, Costello CE,
519 Dell A, Feizi T, Haslam SM, Karlsson N, Khoo K-H, Kolarich D, Liu Y, Novotny M,
520 Packer NH, Paulson JC, Rapp E, Ranzinger R, Rudd PM, Smith DF, Struwe WB,
521 Tiemeyer M, Wells L, Zaia J, Kettner C. 2014. MIRAGE: the minimum information
522 required for a glycomics experiment. Glycobiology 24:402–406.

523 26. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt
524 SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y,
525 Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel
526 GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing
527 human monoclonal antibodies to HIV-1. Science 329:856–861.

528 27. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K,
529 Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12
530 defines a distinctive neutralization epitope on the gp120 glycoprotein of human
531 immunodeficiency virus type 1. J Virol 70:1100–1108.

532 28. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. 2004. The
533 V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human
534 Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly
535 Induced upon Infection. J Virol 78:5205–5215.

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

536 29. Chen Y, Vaine M, Wallace A, Han D, Wan S, Seaman MS, Montefiori D, Wang S,
537 Lu S. 2013. A novel rabbit monoclonal antibody platform to dissect the diverse
538 repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol 87:10232–
539 10243.

540 30. Pan R, Chen Y, Vaine M, Hu G, Wang S, Lu S, Kong X-P. 2015. Structural analysis
541 of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4
542 region critical for receptor and co-receptor binding. Emerg Microbes Infect 4:e44.

543

544

Journal of Virology JVI Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

545

Figure legends

547

548 Figure 1. A. Sequences of the gp120 proteins belonging to clade A (92UG037.8), B
549 (JRFL), C (93MW965.26), and AE (consensus) aligned to the reference strain HXB2.
550 Identical amino acids are shown as dots, gaps are indicated with dashes, numbers
551 correspond to the HXB2 sequence. Variable regions V1-V5 of gp120 are indicated
552 above the sequences. PNGSs predicted based on the consensus glycosylation
553 sequence are shown in red font and marked with stars above the sequences. B.
554 Summary of glycosylation site distribution among the four gp120 proteins. N indicates
555 the presence of the PNGS in the sequence.

556

557 Figure 2. A. Representative MS spectra of glycans identified on research grade gp120
558 proteins produced in CHO cells (top) and 293F cells (bottom); The gp120 protein from
559 clade B (strain JR-FL) protein is shown here as a representative example. Glycan forms
560 corresponding to the most abundant peaks are shown using the standard glycan icons.
561 Mass peaks corresponding to oligomannose and complex glycan forms are indicated.
562 B. Quantitative comparison of relative proportions of various glycan forms (in %) on
563 CHO- and 293F-derived gp120-B proteins. Glycan structures found at proportions
564 greater than 10% of total glycans are highlighted in grey.

565

566 Figure 3. A. PNGS occupancy analysis of gp120 proteins expressed in 293F cells (top
567 row) and CHO cells (bottom row). The percent of glycan occupancy at each PNGS are

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

568 shown for each of the gp120 proteins (clades A, B, C and AE) as indicated on the top of
569 each panel. Green and purple bars indicate the percent of oligomannose glycans and
570 complex glycans, respectively, and grey bars means the site was not occupied by a
571 glycan. ND indicates peptides not detected. B. Differences (%) in glycan occupancy
572 between the 293F- and CHO-produced proteins at each PNGS for each of the gp120
573 proteins. Percentages for oligomannose and complex glycans were compared at each
574 site and the difference was plotted based on which protein had larger amount of that
575 glycan. For example, at position N187 in clade A protein, 293F-derived protein had 25
576 percentage points more complex glycans than CHO-derived protein, while CHO-derived
577 protein had 18 percentage points more oligomannose glycans than 293F-derived
578 protein.
579
580 Figure 4. MS spectra of glycans released from four gp120 proteins (A, B, C and AE)
581 produced under GMP conditions. Glycan forms corresponding to the most abundant
582 peaks are shown using the standard glycan icons. Spectra corresponding to
583 oligomannose and complex glycan forms are highlighted below.
584
585 Figure 5. Quantitation of the types of glycan forms released from two independent lots
586 (Lot 1 & Lot 2) of gp120 proteins (A, B, C and AE) produced under GMP conditions.
587 Numbers indicate the percentages of the corresponding glycan forms or structural
588 classes as color coded for Man5 (M5), Man6 (M6), Man7 (M7), Man8 (M8), Man9 (M9),
589 Pauci (Man 3 and Man4), Hybrid, and Complex.
590

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

591 Figure 6. The analysis of sialylation (left panel) and core fucosylation (right panel)
592 modifications of complex glycans of each gp120 protein (A, B, C or AE) produced from
593 2 different GMP lots. Only complex glycans were included in the analysis. “1” and “2”
594 under each bar of the graph indicate lot 1 and lot 2 GMP-grade gp120 proteins,
595 respectively. “A”, “B”, “C” and “AE” at the bottom of the graph indicate gp120 protein
596 from clades A, B, C and AE, respectively.
597
598 Figure 7. A. PNGS occupancy analysis of GMP-grade gp120 proteins.
599 The percent of glycan occupancy at each PNGS is shown for each of the gp120
600 proteins (clades A, B, C and AE) as indicated on the top of each panel. Green and
601 purple bars indicate the oligomannose glycans and complex glycans, respectively, and
602 grey bars means the site was not occupied by a glycan. ND indicates peptides not
603 detected. B. Differences (%) in glycan occupancy in gp120 proteins produced in CHO
604 cells under research-grade conditions and under GMP conditions at each PNGS. The
605 plots were generated as described in Figure 3B.
606
607
608

Journal of Virology
JVI
Journal of Virology
Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

609

Table 1. Binding affinity of two GMP lots of gp120 proteins, K_d (M)

GMP gp120 proteins	gp120 specific mAb						IgG-CD4
	CD4bs	Glycan		V2	V3	C4	
	VRC01	2G12	PGT128	2158	R16	R53	
Clade A Lot 1	6.04E-09	3.11E-10	7.68E-10	6.85E-09	5.59E-10	6.76E-08	5.48E-09
Clade A Lot 2	5.96E-09	1.80E-10	7.62E-10	6.46E-09	2.81E-10	2.76E-08	3.62E-09
Clade B Lot 1	3.11E-08	<1.0E-12	2.46E-09	4.55E-09	3.49E-10	1.16E-08	7.44E-09
Clade B Lot 2	2.83E-08	<1.0E-12	2.10E-09	3.26E-09	4.56E-10	1.32E-08	4.87E-09
Clade C Lot 1	4.53E-08	5.54E-09	3.25E-08	2.61E-08	3.80E-10	5.63E-09	1.57E-07
Clade C Lot 2	5.21E-08	2.24E-09	2.03E-08	3.31E-08	4.27E-10	4.98E-08	1.15E-07
Clade AE Lot 1	5.25E-08	8.02E-09	3.71E-08	3.05E-08	5.87E-10	8.89E-09	2.46E-08
Clade AE Lot 2	3.53E-08	8.62E-09	2.62E-08	3.32E-08	3.22E-10	5.63E-09	1.84E-08

610

Journal of Virology JVI Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Fig 1. gp120 sequence alignment

A.

```
     31                                                                          *                                            *
HXB2 TEKLWVTVYY GVPVWKEATT TLFCASDAKA YDTEVHNVWA THACVPTDPN PQEVVLVNVT ENFNMWKNDM VEQMHEDIIS LWDQSLKPCV KLTPLCVSLK
A       ....... ......D.E. .......... .......... .......... ...IYME... .E......N. .....T.... .......... Q......T.D
B    .......... .......... .......... .......... .......... .......... .H......N. ....Q..... .......... .......T.N
C       ....... ........K. ......E... .......... .......... ...MV.E... .......... .N........ .......... .......T.N
AE      ....... ......D.D. .......... HE........ .......... ...IH.E... ........N. ....Q.D... .......... .......T.N

     |<------- V1 ------->|<------------- V2 ------------->|
         *  *   *     *    * *                   **         *                                         220
HXB2 CTDLKNDTNT --NSSSGRMIME KG---EIKNCSFN ISTSIRGKVQ KEYAFFYKLD IIPID---NDTT-S YKLTSCNTSV ITQACPKVSF EPIPIHYCAP
A    .SY--.I..- --.ITNSITNSS VNMRE........ MT.EL.D.NR .V.SL..... VVQ.NNG-NNSSNL .R.IN....A L.......T. .....R....
B    .KDV-.A..T T-.D.E.-TME- ---RG........ .T....DEV. .E..L..... VV...N--.NTS-- .R.IS.D... .......I.. ..........
C    ..NA-.G..N --.GTVNV-NDT M--YG........ MT.EL.D.KK QV..L..... .VSLNENS.NSSE- .R.IN..... ........T. D.........
AE   ..NA-.L..N NI.G.NIIGNIT ----D.VR..... MT.EL.D.K. ..H.L..... IVQ.EDNS.-SSE- .R.IN..... .......I.. D.......T.

                                                                                   |<------------ V3 -------
              *    *      *                    *             *             *      *      *                  320
HXB2 AGFAILKCNN KTFNGTGPCT NVSTVQCTHG IRPVVSTQLL LNGSLAEEEV VIRSVNFTDN AKTIIVQLNT SVEINCTRPN NNTRKRIRIQ RGPGRAFVTI
A    ..Y......D .E.....L.K .......... .......... ........GK. M...E.I.N. V.NIIVQ..E T.T....... .....--SVR I...QT.YAT
B    .........D .T.N.K...K .......... .......... .......EEV V...D.F.N. ........KE .......... .....--S.H I......Y.T
C    ..Y....... .T.T.I...K .......... .K........ .........I IV..E.L.D. V.....H..E ....V..... .....--SVR I...QT.YAT
AE   ..Y......D .N...T...K ...S...... .K........ .........I I...E.L.N. ......H..K .........N ....T--S.T I...QV.YRT

     ------->|                                                          |<------------ V4 ------------->
              * *    *                 *         *                        *      * *    *      *  *       417
HXB2 GKI-GNMRQAH CNISRAKWNN TLKQIASKLR EQFGNNKTII FKQ-SSGGDPE IVTHSFNCGG EFFYCNSTQL FNSTWF--NSTW STEGSNNTEG SDTITLP
A    .D.I.DI.... ..V.GSQWNR A.HQVVGQ.. .YW--.T... ..N-.....L. .T........ ......TSG. ...N.TH-.D.A .-MKP.D.-- ---....
B    .E.I.DI.... .........D ...Q.VI... ...E-.K..V .-NH....... ..M....... ......S... .....N--.N.E GS---.N.E- GNT....
C    .A.I.DI.... ....TI...K ..QGVEK..K .H.P-.K..E ..P-.....L. .T......R. ...C..TSN. ...NL.TD.L.- --NTT.I.-- -----..
AE   .D.I.DI.K.Y .E.NGT...E V...VTG..K .H.N-.K... .QPP-....L. .TM.H...R. ......TTK. ..N.CIG-.E.M EGC--.G.-- ---.I..

     |                                           |<- V5 ->|
                             *     *              * * *                                         510
HXB2 CRI KQIINMWQKV GKAMYAPPIS GQIRCSSNIT GLLLTRDGGN SNNESEIFRP GGGDMRDNWR SELYKYKVVK IEPLGVAPTK AKRRVVQREK
A    ... ........R. .Q.I.....Q .V...E.... ..I......G NI...Q.... .......... .........R .......... ......E
B    ... ........E. .........R .......... .........I NE.GT..... .......... .......... .......... .......
C    ... ........G. .R.......A .N.T.K.... .........E N-.RT.T... .......... .........E .K.......G ......E
AE   ... ........G. .Q........ .R.N.V.... .I.......A N.TAN.T... ...NIK.... .........Q .....I...R ......E
```

B.

	N88	N130	N136	N139	N141	N143	N148	N156	N160	N186	N187	N197	N230	N234	N241	N262	N276	N289	N295	N301	N332	N334	N339	N356	N363	N386	N392	N394	N397	N403	N406	N442	N448	N461	N463	N465
A	N		N		N		N	N	N	N	N	N		N	N	N	N	N	N	N	N			N	N	N		N	N		N		N		N	
B	N		N	N	N			N	N	N	N				N	N	N		N	N	N		N	N	N	N	N		N		N		N		N	
C	N	N	N		N		N	N	N	N	N	N	N		N	N	N	N		N	N		N	N		N			N	N	N	N	N		N	
AE	N	N	N			N	N	N	N	N		N		N	N	N	N	N	N	N		N		N		N	N		N		N		N	N		N

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online
Journal of Virology
JVI
Journal of Virology

Fig 2. Glycoform analysis of clade B gp120 proteins expressed in CHO and 293F cells.



Glycan	CHO	293
M3	2.4	0.7
M4	7.0	1.2
M5	8.5	7.0
M6	5.5	5.2
M7	7.6	8.8
M8	14.0	17.0
M9	12.2	18.6
N2M3N2F	2.0	13.8
LacNAc2M3N2F	8.7	3.7
LacNAc3M3N2F	1.2	0.9
NA1LacNAc1GN2M3N2F	14.1	7.9
NA1G1N3M3N2F	0.6	3.4
NA1LacNAc1GN2M3N2F	0.3	2.1
NA2G2N2M3N2F	8.9	4.2
NA1LacNAc2GNM3N2F	1.9	1.6
NA2G2N3M3N2F	0.1	1.0
NA2LacNAc1G2N2M3N2F	2.4	0.4
NA3G3N3M3N2F	1.7	1.0
NA2LacNAc2G2N2M3N2F	0.3	0.5
NA3LacNAc1G3N3M3N2F	0.3	0.5
NA4G4N4M3N2F	0.3	0.4
Total	100	100

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Fig 3. A. PNGS occupancy analysis of gp120 proteins expressed in CHO and 293F cells. B. Differences in glycosylation between 293- and CHO-produced proteins.



Accepted Manuscript Posted Online

Fig 4. Glycan profiles of gp120 proteins produced by GMP manufacturing.



Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online
Journal of Virology
JVI
Journal of Virology

Fig 5. Glycan profiles of gp120 proteins produced by GMP manufacturing.



Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Journal of Virology

JVI

Fig 6. Sialylation and core fucosylation of GMP grade gp120s.



Journal of Virology

Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH

Accepted Manuscript Posted Online

Fig 7. Glycan occupancy analysis of GMP-grade proteins.



Downloaded from http://jvi.asm.org/ on February 24, 2020 at UNIV OF MASS MED SCH